Key points from article :
A London-based start-up developed a nutritional Longevity supplement that it claims will counteract age-related neurodegeneration.
The patent-pending compound, Mitocholine, combines dicholine succinate and nicotinamide.
The company’s approach is based on the finding that insulin action in the brain is dependent on succinate oxidation in mitochondria. Dicholine succinate was found to be the best for the activation of brain insulin.
It addresses the drop in energy our brains experience as we age.
Mitocholine has already recognised as safe designation from the US FDA.
“We could already make marketing claims, but we want to prove that Mitocholine has an effect,” Larisa Andreeva, co-founder and CEO.
The trial will focus on 100 patients suffering from mild cognitive impairment.
“The clinical trial will....communicate the benefit to customers and patients,” - Andreeva.
Received approximately £600,000 in seed funding and is now seeking Series A funding to take it through the clinical trial.
